FDA Approves SetPoint Neuroimmune Modulation Device for Rheumatoid Arthritis
The FDA has approved the innovative SetPoint System, a neuroimmune device designed to activate the body's natural anti-inflammatory pathways for treating rheumatoid arthritis, offering hope for patients resistant to conventional therapies.
The U.S. Food and Drug Administration has granted approval for the SetPoint System, an innovative neuroimmune modulation device designed to treat adults suffering from moderate-to-severe rheumatoid arthritis (RA). This groundbreaking device is intended for individuals who do not experience adequate relief from or cannot tolerate existing advanced RA treatments, including biological and targeted synthetic disease-modifying antirheumatic drugs (DMARDs).
The SetPoint System is an implantable device that uniquely delivers electrical stimulation to the vagus nerve once daily. This stimulation aims to activate the body's natural anti-inflammatory and immune-restorative pathways, offering a new approach to managing autoimmune inflammation. The device's approval follows positive results from the RESET-RA clinical trial, which involved 242 participants randomly assigned to receive either the SetPoint Device or a sham device.
In the study, the primary goal was to achieve a 20% improvement according to the American College of Rheumatology criteria after three months. The trial successfully met this endpoint, with participants showing sustained improvements in response rates and disease activity over 12 months. Notably, about 75% of the patients managed to stay off biologic or targeted synthetic DMARDs after a year. The implantation procedure and subsequent stimulation were well tolerated, with a low side effect rate of 1.7% for serious adverse events.
According to Dr. Mark Richardson of Harvard University, who led the trial, the approval underscores the promising potential of neuroimmune modulation as a novel therapy for autoimmune diseases. After a minimally invasive outpatient procedure, the device is programmed to operate automatically on a set schedule, with a lifespan of up to 10 years, simplifying ongoing care for RA patients.
The SetPoint device has been approved for use by SetPoint Medical, marking a significant advancement in rheumatoid arthritis treatment options.
source: https://medicalxpress.com/news/2025-08-fda-setpoint-neuroimmune-modulation-device.html
Stay Updated with Mia's Feed
Get the latest health & wellness insights delivered straight to your inbox.
Related Articles
New Insights into Bone Repair: Discovering Four Key Subtypes of Skeletal Stem Cells
Recent research uncovers four major subtypes of skeletal stem cells responsible for bone repair, revealing how aging shifts this balance and opening new possibilities for regenerative therapies. Learn how scientists are advancing bone healing and health.
The Promising Role of Vaccines in Combating Dementia
Emerging research indicates that vaccines, particularly for shingles, may significantly reduce the risk of dementia. This groundbreaking study suggests a new therapeutic avenue for neurodegenerative diseases, emphasizing the broader potential of vaccines beyond infection prevention.
Fact Check: RFK Jr.'s Claims About mRNA Vaccines Lack Scientific Support
Debunking RFK Jr.'s claims, this article reviews scientific evidence supporting the effectiveness of mRNA vaccines in preventing severe COVID-19 outcomes and clarifies misconceptions about their ability to block all respiratory infections.
Revised Adult Sinusitis Guidelines Highlight Patient Education and Shared Decision-Making
The AAO-HNSF has published updated guidelines for adult sinusitis, emphasizing patient education, shared decision-making, and evidence-based management to improve outcomes and reduce unnecessary antibiotic use.